Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cetirizine Dihydrochloride
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Nicox SA
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zerviate (cetirizine hydrochloride) is a histamine-1 (H1) receptor antagonist. Its effects are mediated via selective inhibition of H1 histamine receptors. It is approved in China for ocular itching associated with allergic conjunctivitis.
Product Name : Zerviate
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 14, 2023
Lead Product(s) : Cetirizine Dihydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Nicox SA
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OT-101 (atropine sulfate eye drops) inhibits the muscarinic actions of acetylcholine, which is investigated for dry eye syndrome and Myopia Progressive.
Product Name : OT-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 06, 2023
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetirizine Dihydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Nicox SA
Deal Size : Inapplicable
Deal Type : Inapplicable
Nicox's Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE in China
Details : ZERVIATE is the first and only eye drop formulation of the antihistamine cetirizine, the active ingredient in ZYRTEC®, and is currently commercialized in the U.S. for ocular itching associated with allergic conjunctivitis.
Product Name : Zerviate
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 03, 2022
Lead Product(s) : Cetirizine Dihydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Nicox SA
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OT-101 (atropine sulfate eye drops) inhibits the muscarinic actions of acetylcholine, which is investigated for anti-allergy and dry eye syndrome and Myopia, Progressive.
Product Name : OT-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 16, 2021
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OT-101 (atropine sulfate eye drops) inhibits the muscarinic actions of acetylcholine, which is investigated for dry eye syndrome and Myopia Progressive.
Product Name : OT-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 13, 2021
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Ora, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OT-101 (atropine sulfate eye drops) inhibits the muscarinic actions of acetylcholine, which is investigated for dry eye syndrome and Myopia Progressive.
Product Name : OT-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 04, 2021
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Ora, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OT-101 (atropine sulfate eye drops) inhibits the muscarinic actions of acetylcholine, which is investigated for dry eye syndrome and Myopia Progressive.
Product Name : OT-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 20, 2021
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OT-101 (atropine sulfate eye drops) inhibits the muscarinic actions of acetylcholine, which is investigated for dry eye syndrome and Myopia Progressive.
Product Name : OT-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 19, 2021
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Ora, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OT-101 (atropine sulfate eye drops) inhibits the muscarinic actions of acetylcholine, which is investigated for dry eye syndrome and Myopia Progressive.
Product Name : OT-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 22, 2021
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Ora, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Ora, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OT-101 (atropine sulfate eye drops) inhibits the muscarinic actions of acetylcholine, which is investigated for dry eye syndrome and Myopia Progressive.
Product Name : OT-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 22, 2021
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Ora, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable